Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Abstract

Clinical Trials Registration:

NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

• Authors: Vimalanand S Prabhu, Oliver A Cornely, Yoav Golan, Erik R Dubberke, Sebastian M Heimann, Mary E Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 65 Issue 7 Pg. 1218-1221 (10 01 2017) ISSN: 1537-6591 [Electronic] United States
• PMID: 30060024 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Antibodies, Monoclonal
• Antibodies, Neutralizing
• Broadly Neutralizing Antibodies
• bezlotoxumab

Topics

• Aged
• Anti-Bacterial Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Neutralizing (therapeutic use)
• Broadly Neutralizing Antibodies
• Clostridioides difficile (drug effects)
• Clostridium Infections (drug therapy)
• Double-Blind Method
• Humans
• Middle Aged
• Patient Readmission
• Recurrence